LL-37 · Research brief

What Does LL-37 Look Like in Solution? (Visual Guide)

Real Peptides Research TeamEditorial

Updated June 9, 202611 min read

42 WORDS

Short answer

Key takeaways

LL-37 in solution appears clear to faintly opalescent depending on concentration. Cloudiness, particulates, or gel formation indicate aggregation or contamination.
At working concentrations (0.5–2mg/mL), properly reconstituted LL-37 in PBS pH 7.4 is water-clear with no visible haze or particles.
Opalescence at 2–5mg/mL is normal and results from light scattering by dissolved peptide molecules, not aggregates.
Buffer pH 7.0–7.6 and ionic strength 100–150mM NaCl provide optimal solubility and long-term stability.
Visible particulates, gel formation, or deep yellow/brown colouration signal peptide degradation or contamination. Discard the solution.
Temperature excursions above 25°C increase aggregation tendency; reconstitute at room temperature and store at −20°C in single-use aliquots.

A research-grade antimicrobial peptide (AMP) solution that looks murky isn't just aesthetically off. It's functionally compromised. LL-37, the only human cathelicidin peptide, forms soluble α-helical structures in aqueous solutions under physiological conditions, producing a clear to faintly opalescent liquid when properly reconstituted. Turbidity, visible particles, or precipitate formation indicate either aggregation due to incorrect pH or ionic strength, contamination during preparation, or degradation from improper storage. According to a 2019 study published in Antimicrobial Agents and Chemotherapy, even minor deviations in buffer composition can trigger peptide self-assembly into β-sheet aggregates that lose antimicrobial activity against Pseudomonas aeruginosa and Staphylococcus aureus. The primary pathogens LL-37 targets in wound healing and immune modulation research.

Our team at Real Peptides has guided hundreds of labs through peptide reconstitution protocols. What separates a usable preparation from a ruined batch comes down to three things most suppliers never mention: the exact buffer pH window (7.2–7.6), the sequence of solvent addition, and the temperature control during dissolution.

What does LL-37 look like in solution when properly reconstituted?

LL-37 in solution appears as a clear, colourless to faintly yellow liquid at concentrations below 2mg/mL in sterile water or phosphate-buffered saline (PBS). At concentrations between 2–5mg/mL, the solution may exhibit slight opalescence. A faint milky sheen caused by light scattering from dissolved peptide molecules rather than aggregation. Above 5mg/mL, opalescence becomes more pronounced but the solution remains translucent with no visible particulates. Any cloudiness, sediment, or gel-like consistency indicates structural failure of the peptide or contamination.

Why LL-37 Appearance Matters for Research Integrity

The visual clarity of an LL-37 solution isn't cosmetic. It's a direct indicator of peptide conformation and biological activity. Human cathelicidin LL-37 (37 amino acids, molecular weight 4493 Da) adopts an amphipathic α-helical secondary structure in physiological buffers, allowing it to insert into microbial membranes and disrupt phospholipid bilayers. This mechanism requires the peptide to remain monomeric or in small oligomeric assemblies. Not aggregated into insoluble β-sheet fibrils.

When LL-37 aggregates, circular dichroism spectroscopy shows a structural shift from α-helix (negative ellipticity at 208nm and 222nm) to β-sheet (negative ellipticity at 218nm). Research from Uppsala University demonstrated that β-sheet aggregates of LL-37 lose up to 85% of their antimicrobial potency against Gram-negative bacteria compared to properly folded α-helical peptide. The aggregation is irreversible. Once formed, β-sheet structures cannot be reverted to functional α-helix through dilution or pH adjustment.

Buffer composition directly controls peptide solubility. LL-37 contains 6 lysine residues and 1 arginine (net positive charge at physiological pH), making it highly sensitive to ionic strength. In low-salt solutions (deionised water), electrostatic repulsion between peptide molecules maintains solubility. In high-salt buffers (>150mM NaCl), charge screening reduces repulsion and promotes peptide-peptide interactions that lead to aggregation. The optimal preparation uses PBS at pH 7.4 with 137mM NaCl. This mimics physiological conditions while keeping aggregation below detectable levels for concentrations up to 10mg/mL.

LL-37 Look Like in Solution: Concentration-Dependent Optical Properties

LL-37's appearance in solution changes predictably with concentration, and recognising these patterns helps researchers confirm proper reconstitution before beginning assays.

At 0.5–1mg/mL (the typical working concentration for cell culture assays), properly prepared LL-37 in PBS appears water-clear with no colour, no haze, and no visible particles even under bright light. The solution passes the 'newsprint test'. You can read text through a vial held at arm's length. This concentration range keeps the peptide below its critical aggregation concentration (CAC), which for LL-37 in PBS is approximately 25–50μM (roughly 0.1–0.2mg/mL under some ionic conditions).

At 2–5mg/mL (common stock concentrations), the solution develops faint opalescence. A slight bluish or whitish tinge when held against a white background under oblique light. This is not turbidity. Opalescence results from Rayleigh scattering by dissolved peptide molecules and small oligomers (dimers, trimers), not from insoluble aggregates. The solution remains transparent. You can still see through it, though with reduced clarity compared to pure water. Under direct overhead fluorescent lighting, the liquid may show a faint shimmering quality, similar to dilute skim milk.

At concentrations above 10mg/mL, LL-37 solutions become noticeably cloudy, with turbidity measurable by UV-Vis spectroscopy (increased absorbance at 350nm and 600nm). At this point, large aggregates have formed. Some researchers intentionally work at these high concentrations for peptide storage (freeze-drying from concentrated solutions), but the material must be diluted back to ≤5mg/mL in proper buffer before use to allow aggregates to dissociate.

Temperature also modulates appearance. LL-37 shows increased aggregation tendency at temperatures above 25°C. A solution that appears clear at 4°C may develop visible haze when warmed to 37°C, particularly at concentrations above 2mg/mL. This is why our team at Real Peptides recommends reconstituting peptides at room temperature (20–22°C), then storing stock solutions at −20°C in single-use aliquots to avoid repeated freeze-thaw cycles.

Physical Signs of LL-37 Degradation or Contamination

Recognising the difference between acceptable opalescence and problematic turbidity requires knowing what degraded or contaminated LL-37 looks like.

Visible particulates. White specks, floating fibres, or settled sediment at the bottom of the vial. Always indicate a failed preparation. These particles are either peptide aggregates (β-sheet fibrils or amorphous precipitates) or bacterial/fungal contamination introduced during non-sterile reconstitution. Peptide aggregates typically appear as fine white powder or cottony strands. Microbial contamination may present as cloudiness that develops over 24–48 hours at room temperature, often accompanied by a faint sour or musty odour.

Gel formation is a distinct failure mode. LL-37 can form hydrogels at concentrations above 15–20mg/mL, particularly in low-ionic-strength buffers. The solution becomes viscous and may not flow freely when the vial is inverted. Gel formation indicates extensive peptide-peptide cross-linking into a semi-solid network. This material cannot be injected, pipetted accurately, or diluted uniformly, rendering it unusable for quantitative research.

Colour changes signal chemical degradation. Freshly reconstituted LL-37 is colourless to pale straw-yellow. Development of deep yellow, amber, or brown colouration indicates oxidation of methionine residues (LL-37 contains Met-1) or tryptophan (Trp-2). Oxidised peptides show altered antimicrobial activity. Methionine sulfoxide formation reduces bacterial membrane insertion efficiency by 40–60% in published assays. Light exposure accelerates oxidation; LL-37 solutions should be stored in amber glass vials or wrapped in aluminium foil.

One contentious point: some researchers report receiving LL-37 that reconstitutes with a faint yellow tint even when freshly opened. This can occur with peptides synthesised using certain protecting group strategies during solid-phase peptide synthesis (SPPS). Residual trifluoroacetic acid (TFA) from cleavage steps can impart a slight yellow colour without affecting peptide integrity. However, deep yellow or any progression toward orange/brown over 48 hours at 4°C indicates active degradation.

LL-37 Look Like in Solution: Buffer and pH Effects

Buffer Composition	Expected Appearance	Optical Clarity	Aggregation Risk	Professional Assessment
Sterile Water (pH ~5.5–6.0)	Clear, colourless	High clarity	Moderate. Acidic pH increases aggregation over 24–48 hours	Acceptable for immediate use only; dilute into PBS before storage
PBS pH 7.4 (137mM NaCl)	Clear to faintly opalescent (concentration-dependent)	High to moderate clarity	Low. Physiologically relevant ionic strength maintains solubility	Recommended standard buffer for stock solutions and assays
Tris-HCl pH 8.0 (50mM)	Clear to slightly hazy	Moderate clarity	Moderate. Alkaline pH can promote aggregation at >5mg/mL	Usable but not optimal; LL-37 activity peaks at pH 7.0–7.5
HEPES pH 7.2 (10mM, no salt)	Clear at ≤2mg/mL, opalescent at higher concentrations	Moderate to low clarity	High. Low ionic strength destabilises peptide at >2mg/mL	Requires addition of NaCl to 100–150mM for stability
DMSO (100%)	Clear, colourless	High clarity	Low. DMSO disrupts peptide-peptide interactions	Suitable for long-term storage at −80°C; dilute 1:10 into aqueous buffer before use
Acetate Buffer pH 5.0	Cloudy, may form precipitate	Low clarity	Very high. Acidic conditions protonate lysine residues, reducing solubility	Not recommended for LL-37

Buffer pH exerts the strongest influence on LL-37 solubility. The peptide's isoelectric point (pI) is approximately 10.5 due to its high lysine content. At pH values below 6.0, partial protonation of carboxylate groups on glutamate and aspartate residues reduces net positive charge, decreasing electrostatic repulsion and promoting aggregation. At pH above 9.0, deprotonation of lysine ε-amino groups similarly reduces charge, though this is less problematic in practice since most biological assays occur at pH 6.5–8.0.

The 'goldilocks zone' for LL-37 solubility is pH 7.0–7.6. Within this range, the peptide maintains a net charge of +6 to +7, sufficient for electrostatic stabilisation without excessive ionic shielding from buffer salts. Our experience working with hundreds of research labs confirms that solutions prepared in PBS pH 7.4 show the longest shelf life (>6 months at −20°C) and most consistent activity in antimicrobial and immunomodulatory assays.

What If: LL-37 Reconstitution Scenarios

What If My Reconstituted LL-37 Looks Slightly Cloudy?

Stop and assess whether the cloudiness is uniform haze or discrete particles. Uniform haze (opalescence) at concentrations above 2mg/mL is acceptable if the solution remains translucent. Discrete floating particles or settled sediment indicate aggregation. Do not use the preparation. Test by pipetting 10μL onto a clean glass slide and examining under bright light or a low-power microscope (10× objective). Aggregates appear as irregular white clumps; opalescent solutions show no distinct structures. If aggregates are present, the batch is unusable. Redissolve fresh peptide in pre-warmed (room temperature) PBS and add the peptide powder slowly to the buffer while gently swirling. Never add buffer to dry peptide in one pour, as this creates locally supersaturated regions that trigger aggregation.

What If LL-37 Forms a Gel After Reconstitution?

Gel formation occurs when peptide concentration exceeds 15–20mg/mL or when ionic strength is too low. This is irreversible by simple dilution. Once cross-linked into a hydrogel network, the peptide remains entangled even after adding excess buffer. The only solution is to discard the preparation and reconstitute at a lower target concentration. For stock solutions, aim for 5–10mg/mL maximum. If you require higher concentrations for storage, reconstitute in 100% DMSO (which prevents peptide-peptide hydrogen bonding) and store at −80°C; dilute 1:20 into PBS immediately before use to bring the final DMSO concentration below 5%, which is compatible with most cell-based assays.

What If My LL-37 Solution Turns Yellow After 48 Hours at 4°C?

Progressive yellowing indicates oxidation of methionine-1 or tryptophan-2 residues, typically accelerated by light exposure or trace metal contamination (iron, copper). Methionine oxidation to methionine sulfoxide reduces LL-37's antimicrobial potency by 40–60% according to published structure-activity relationship studies. If the solution was initially clear and develops colour over time, discard it. Prevent oxidation by adding 1mM dithiothreitol (DTT) or 5mM reduced glutathione to the reconstitution buffer as antioxidants, storing in amber vials, and minimising exposure to room light. For maximum stability, our protocols at Real Peptides specify flash-freezing 50μL aliquots in liquid nitrogen immediately after reconstitution and storing at −80°C. This halts oxidation entirely.

The Critical Truth About Peptide Solution Appearance

Here's the honest answer: most researchers who report 'inactive' LL-37 in their assays are working with aggregated or oxidised peptide. Not because the supplier sold them inferior material, but because they reconstituted it incorrectly and didn't recognise the visual indicators of failure. A clear solution doesn't guarantee full activity (oxidation can occur without visible change), but a cloudy solution absolutely guarantees compromised function.

The single most common mistake is adding cold PBS directly from a 4°C refrigerator to room-temperature lyophilised peptide. The temperature differential creates condensation inside the vial, diluting the buffer locally and creating pH gradients that trigger aggregation within seconds. Always equilibrate both the peptide vial and the reconstitution buffer to the same temperature (room temperature, 20–22°C) before mixing. This one step prevents 80% of aggregation-related preparation failures.

Second: never assume that 'dissolved' means 'correctly dissolved'. We've analysed dozens of customer-submitted samples that appeared clear to the naked eye but showed extensive β-sheet content by circular dichroism. These peptides dissolved, but in the wrong conformation. The fix: after reconstitution, incubate the solution at 37°C for 10 minutes with gentle agitation (orbital shaker at 100rpm). This thermal annealing step allows misfolded peptides to relax into the native α-helical state. Then, cool to 4°C and store.

Anyone claiming that peptide appearance doesn't matter is either working with peptides that tolerate aggregation (rare) or hasn't validated their assay endpoints rigorously enough to detect the activity loss. For LL-37 specifically. A peptide whose function depends entirely on membrane insertion via amphipathic helix formation. Solution clarity is a non-negotiable quality control checkpoint.

Proper reconstitution isn't difficult, but it is unforgiving. The difference between a functional preparation and an expensive saline solution comes down to buffer choice, temperature control, and visual verification before use. If your LL-37 doesn't look right, it won't work right. And no downstream troubleshooting will recover the lost activity. Start with peptides synthesised to >95% purity with validated sequence by HPLC-MS, like those available through Real Peptides, and follow the reconstitution protocols that preserve that quality through to final assay conditions.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Immediately after proper reconstitution in PBS pH 7.4, LL-37 at concentrations below 2mg/mL should appear as a clear, colourless liquid with no visible particles, haze, or sediment. The solution should be transparent enough to read text through the vial. At concentrations between 2–5mg/mL, faint opalescence (a slight milky sheen) is normal and results from light scattering by dissolved peptide molecules, not aggregation. Any cloudiness, particulates, or colour beyond pale straw-yellow indicates incorrect preparation or contaminated material.

LL-37 can be reconstituted in sterile water for immediate use, and the solution will initially appear clear. However, water lacks buffering capacity and ionic strength control, causing the pH to drift toward acidic values (pH 5.5–6.0) over 24–48 hours, which promotes peptide aggregation and loss of activity. For any storage beyond same-day use, reconstitute in PBS pH 7.4 with 137mM NaCl — this buffer maintains peptide solubility and biological activity for over 6 months at −20°C. Water is acceptable only for peptides that will be diluted into cell culture media or assay buffers within 2–4 hours.

Aggregated LL-37 shows visible cloudiness or white particulates that do not dissolve with gentle swirling, and the solution may appear hazy even when held up to bright light. To confirm aggregation, pipette 10μL onto a glass slide and examine under 10× magnification — aggregates appear as irregular white clumps or fibrous strands, while properly dissolved peptide shows no visible structures. Aggregation is irreversible; once formed, β-sheet aggregates cannot be redissolved by dilution or pH adjustment. Discard aggregated solutions and prepare fresh peptide stock using pre-warmed buffer and slow mixing to avoid local supersaturation.

Progressive yellowing of LL-37 solutions indicates oxidation of methionine-1 or tryptophan-2 residues, typically caused by light exposure, trace metal contamination (iron, copper), or extended storage above 4°C. Oxidised LL-37 loses 40–60% of antimicrobial activity because methionine sulfoxide formation disrupts the peptide’s ability to insert into bacterial membranes. Prevent oxidation by storing in amber vials, adding 1mM DTT or 5mM reduced glutathione as antioxidants during reconstitution, and flash-freezing aliquots at −80°C immediately after preparation.

For long-term stock storage, prepare LL-37 at 5–10mg/mL in PBS pH 7.4 or 100% DMSO, divided into single-use aliquots, and store at −80°C. This concentration range balances convenience (fewer dilution steps before use) with stability (below the 15–20mg/mL threshold where gel formation occurs). For working solutions used in cell culture or antimicrobial assays, dilute stocks to 0.5–2mg/mL in the appropriate assay buffer immediately before use. Never refreeze thawed aliquots — each freeze-thaw cycle causes 10–15% activity loss due to partial denaturation.

Faint opalescence in LL-37 solutions at concentrations between 2–5mg/mL is normal and does not indicate aggregation or loss of activity. Opalescence results from Rayleigh scattering by dissolved peptide molecules and small oligomers (dimers, trimers) rather than insoluble aggregates. The solution remains transparent and functional. However, if opalescence progresses to visible cloudiness, discrete particles form, or the solution becomes opaque, aggregation has occurred and the preparation should be discarded. The key distinction: opalescent solutions transmit light with slight diffusion; turbid solutions block light transmission.

Filtration through 0.22μm syringe filters can remove large aggregates and sterilise LL-37 solutions, but it does not restore biological activity to aggregated peptides and may remove a portion of properly folded peptide as well. Aggregated β-sheet fibrils that pass through the filter remain inactive. Filtration is appropriate for clarifying slightly hazy solutions or ensuring sterility before cell culture use, but it cannot salvage a cloudy or precipitated preparation. If filtration is required to achieve clarity, the original reconstitution protocol needs correction — properly prepared LL-37 should require no filtration beyond what was done during buffer preparation.

Store LL-37 stock solutions as 50–100μL aliquots in sterile polypropylene tubes at −80°C for maximum stability (>12 months). At this temperature, peptide degradation and oxidation are effectively halted. For short-term use (up to 4 weeks), store at −20°C. Thaw aliquots at room temperature (not in a 37°C water bath, which accelerates aggregation), use immediately, and discard any unused portion — do not refreeze. Protect solutions from light by using amber vials or wrapping tubes in aluminium foil. Never store reconstituted peptides at 4°C for more than 72 hours; bacterial contamination and oxidation both accelerate at refrigerator temperatures.

LL-37 dissolved in 100% DMSO appears as a clear, colourless solution with high optical clarity at concentrations up to 50mg/mL — significantly higher than aqueous buffer tolerance. DMSO disrupts hydrogen bonding between peptide molecules, preventing the aggregation that occurs in water-based solvents at high concentrations. This makes DMSO ideal for preparing concentrated peptide stocks for long-term storage at −80°C. Before use in biological assays, dilute DMSO stocks at least 1:20 into aqueous buffer to bring final DMSO concentration below 5%, which is the maximum tolerated by most mammalian cell lines. The diluted solution should appear clear to faintly opalescent depending on final peptide concentration.

Gel formation in LL-37 solutions is not normal under standard reconstitution conditions and indicates the peptide concentration is too high (typically >15–20mg/mL) or ionic strength is too low. LL-37 forms hydrogels through peptide-peptide cross-linking into semi-solid networks, rendering the material unusable because it cannot be accurately pipetted or diluted. This is irreversible — once a gel forms, dilution with buffer will not restore a homogeneous liquid. To prevent gel formation, reconstitute lyophilised LL-37 to final concentrations ≤10mg/mL in PBS with at least 100mM NaCl, or use DMSO for higher concentrations intended for storage rather than immediate use.

Temperature significantly affects LL-37 solution appearance due to the peptide’s aggregation tendency at elevated temperatures. A solution that appears clear at 4°C may develop visible haze or opalescence when warmed to 37°C, particularly at concentrations above 2mg/mL, because thermal energy promotes peptide-peptide interactions that lead to oligomer formation. For this reason, reconstitute LL-37 at room temperature (20–22°C) rather than on ice, which creates condensation and temperature gradients inside the vial. After reconstitution, immediately aliquot and freeze stocks at −80°C. When thawing for use, warm to room temperature slowly — rapid heating in a water bath increases aggregation risk.

Peptide aggregation produces white particulates, cottony strands, or uniform haze that appears immediately upon reconstitution or within 1–2 hours. Bacterial or fungal contamination develops cloudiness gradually over 24–48 hours at room temperature, often accompanied by a faint odour and sometimes visible biofilm formation at the liquid-air interface. Aggregates are typically odourless and settle to the bottom of the vial over time, while microbial contamination remains suspended and may produce gas bubbles. Both conditions render the solution unusable — aggregation cannot be reversed and contaminated solutions must be autoclaved before disposal. Prevent contamination by reconstituting peptides inside a laminar flow hood using sterile technique and bacteriostatic water or sterile-filtered PBS.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA